AddedRisk Factors
•multiple, conflicting and changing laws and regulations such as tax laws, privacy and data protection laws and regulations, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
•obtaining regulatory approvals or clearances where required for the sale of our products in various countries;
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
•natural disasters, political and economic instability, including wars, terrorism, social or political unrest, including civil unrest, protests, and other public demonstrations, outbreaks of disease, pandemics or epidemics, boycotts, curtailment of trade, and other market restrictions;
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
•uncertainty surrounding the impact of the Trump Administration’s efforts to deliver MFN drug pricing to American patients on drug prices in international markets;
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
We are subject to public health crises, which have had and may in the future have a significant impact on our operations, cash flows and liquidity. The response to a public health crisis may affect the global economy, disrupt global supply chains, and create significant disruption in financial and healthcare markets, including U.S. staffing shortages, our ability to access customers, and significant volatility in our results of operations due to the periodic cancellation or delay of elective MACI surgical procedures. Uncertainty caused by pandemics, epidemics, or other similar public health crises could lead to prolonged economic downturns and reduce or delay demand for our products, in which case our results of operations could be significantly impacted. The extent to which a public health crisis impacts our business, results of operations, and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including the timing or effectiveness of vaccine roll-outs globally, the timing of easing of preventative or mitigation measures or mandates, the impact of any variants that emerge, or any impact of a global vaccine roll-out on the global economy.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
EU regulation also governs our business. For example, in 2016, the EU adopted a new regulation governing data practices and privacy called the General Data Protection Regulation (“GDPR”), which became effective on May 25, 2018. The GDPR applies to any company established in the EU as well as to those outside the EU if they collect and use personal data in
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
We face competition in the markets targeted by our products. Many of our competitors have substantially greater resources than we do, and we expect that all of our products will face competition from existing or future products, which may impact our ability to successfully commercialize our products.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
All of our products face competition from other surgical procedures as well as existing and future products marketed by large companies. These competitors may successfully market products that compete with our products, identify and bring to market new product candidates earlier than we do, or develop products that are more effective or less costly than our products. These competitive factors could require us to conduct substantial new research and development activities to establish new product targets, which would be costly and time consuming. These activities can adversely impact our ability to effectively commercialize products and achieve revenue and profits.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Further, geopolitical tensions between Taiwan and China have risen steadily over the past year. Although Taiwan has been governed independently from China since 1949, China views Taiwan as part of its territory and has vowed to eventually unify Taiwan with China, using military force if necessary. War or other military conflict in or near Taiwan, pandemics, and certain natural disasters, such as earthquakes, which are commonplace in Taiwan (where CBC is located) may result in the destruction or disruption of CBC’s ability to supply Bromelain SP to MediWound and have downstream implications for our Company.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
and other governments, and any further changes in U.S. or international trade policy could have an adverse impact on our business.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
For example, we are currently evaluating the feasibility and potential market opportunity involved in delivering MACI treatment to patients suffering from cartilage damage in the ankle. We believe that this potential lifecycle enhancement and indication expansion for MACI will require conducting an additional randomized clinical trial concerning the product’s use in the ankle. We conducted pre-IND interactions with the FDA concerning our clinical development program for MACI to treat cartilage injuries in the ankle, and based on feedback from the FDA, our team is actively working to finalize our non-clinical testing and propose a clinical development plan/protocol to FDA for review. We are on track to initiate a MACI Ankle clinical trial later in 2025.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
down and has nearly shut down several times in recent years. During previous shutdowns, certain regulatory agencies, including the FDA, have had to furlough essential employees and stop critical activities. If a prolonged government shutdown occurs in the future, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Furthermore, there have been and continue to be a number of initiatives at the federal and state levels that seek to reduce healthcare costs. In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act of 2010, as
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
amended by the Health Care and Education Reconciliation Act (jointly, the ACA), which includes measures to significantly change the way health care is financed by both governmental and private insurers.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
also involve the improper use of information obtained in the course of patient recruitment for clinical trials. See the section entitled, “Business — Government Regulation — Other Healthcare Laws”.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
competitive advantage, and MediWound may be unable to adequately develop new technologies and obtain future patent protection to preserve our competitive advantage or avoid adverse effects on our business.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedRisk Factors
Generally, if any FDA inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulation occurs independent of such an inspection or audit, we or the FDA may require remedial measures that may be costly and/or time consuming for us or a third-party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales, recalls, warning letters, market withdrawals, seizures, placement of a non-U.S. facility on an import alert, or the temporary or permanent closure of a facility.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
To the extent the ongoing military conflicts in the Middle East region involving Israel intensify or expand were to result in the region and damage to MediWound’s facilities in Israel are damaged or destroyed, inhibit travel or commercial shipments to and from Israel is halted or inhibited, shipments of NexoBrid or NexoBrid related materials are destroyed, or significant key MediWound operational personnel are called to military service, Israel, MediWound’s ability to continue to supply NexoBrid to the U.S. market could be disrupted.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Disruptions at the FDA and other agencies may also slow the time necessary to review and/or approve product candidates or changes to existing products, approve the qualification of the Burlington manufacturing facility and/or conduct required inspections of our and/or third-party manufacturing and testing facilities, and approve and/or inspect third-party contractors and/or potential new or alternate suppliers of materials used in our MACI and Epicel cell manufacturing processes, all of which would adversely affect our business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If the technology that we use infringes a patent held by others, or if the technology utilized by MediWound in development and manufacturing NexoBrid infringes another’s patent, we could be sued for monetary damages by the patent holder or its licensee, or we could be prevented from continuing research, development, and commercialization of products that rely on that technology, unless a license is obtained to use the patent.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Finally, if we are unable to continue to develop and market new products and technologies (such as MACI Arthro) in a timely manner, the demand for our recently products may decrease or our products could become obsolete, and our revenue may decline or our growth prospects may be adversely affected.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If any of our manufacturers or suppliers fails to perform its respective obligations, or if our supply of certain components, equipment, disposable devices and other materials is limited or interrupted, it could impair our ability to manufacture our products, which would delay our ability to market our commercial products or future product candidates or conduct clinical trials on a timely and cost-competitive basis, if at all.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although the length and impact of the ongoing conflict conflicts in Ukraine and the Middle East region is and political and military developments in South America are highly unpredictable, the geopolitical uncertainty caused by the conflicts and developments has led to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions, which has contributed to sustained high levels of inflation globally.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In the last year, the The FTC has announced that it will begin enforcing the Health Breach Notification Rule, and has entered into at least one consent order with a different organization that involved a $1.5 million fine. enforced the Rule several times.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Further, navigating continually evolving legal and regulatory requirements associated with implementing artificial intelligence tools that may be inconsistent from jurisdiction to jurisdiction may require significant resources to help ensure compliance with U.S. law. law or various international laws or limit our ability to incorporate certain artificial intelligence capabilities into our operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Additionally, the escalation of hostilities instabilities and tensions in the Middle East region involving Israel, the initiation of a military conflict between Taiwan and China or the imposition or a trade embargo or blockade affecting Taiwan Israel could negatively affect MediWound’s ability to supply NexoBrid to the U.S. market.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, ongoing conflict between conflicts in Russia and Ukraine and the ongoing conflicts in the Middle East region involving Israel, Region and political and military developments in South America, and sustained high levels of inflation.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although, to date, our business has not been materially impacted by the ongoing military conflict between conflicts in Russia and Ukraine or the ongoing conflict in the Middle East region, region or the political and military developments in South America, geopolitical tensions, or sustained high levels of inflation, it is impossible to predict the extent to which our operations will be impacted in the short and long term, or the ways in which such matters may impact our business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
To the extent that we or others develop new technologies that address the targeted application for our products, our business will may suffer.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our success depends in large part largely upon the efforts of our key management and manufacturing and quality staff.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Finally, our Burlington facility, discussed more fully above, is designed to meet both U.S. and global manufacturing requirements, which provides strategic flexibility to potentially commercialize MACI outside the U.S., and we are currently evaluating introducing MACI in additional geographies. We are currently focused on obtaining regulatory and marketing approval for MACI in the United Kingdom through the Medicine and Healthcare products Regulatory Agency (“MHRA”) and, if successful, anticipate commercializing MACI in the United Kingdom in 2027.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
submitted in 1999. HUDs are devices that are intended for diseases or conditions that affect fewer than 8,000 individuals annually in the U.S., and, for certain HUDs, the amount a manufacturer may charge for the product’s use is restricted.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
by pooling accounts receivable based on similar risk characteristics. The loss percentage is calculated through the use of forecasts that are based on current and historical economic and financial information.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
See “Risk Factors “Our success depends, in part, on the commercial success of NexoBrid for the removal of eschar in adults with deep partial thickness and/or full thickness thermal burns.”
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
In May 2019, we entered into exclusive license and supply agreements with MediWound, under which MediWound manufactures and supplies NexoBrid to the U.S. market on a unit price basis. MediWound develops and manufactures NexoBrid, in part, at its facilities in Yavne, Israel.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
We continue to monitor the ongoing conflicts in the Middle East region involving Israel, and we are in close communication with MediWound leadership. MediWound’s NexoBrid manufacturing operations are continuing and, as of the date of this disclosure, MediWound does not anticipate a material disruption to its ongoing supply of commercial NexoBrid to the United States. To the extent the conflicts in the Middle East region intensify or expand and MediWound’s facilities in Israel are damaged or destroyed, travel to and from Israel is halted or inhibited, or significant key MediWound operational personnel are called to military service, MediWound’s ability to continue to supply NexoBrid to the U.S. market could be disrupted. As of the date of this report, we maintain an ample supply of NexoBrid at our U.S.-based third-party logistics provider.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
For a discussion of additional risks associated with the ongoing conflicts in the Middle East, please see Part I, Item 1A. “Risk Factors”.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
The following table summarizes research and development expenses, which include materials, professional fees and an allocation of employee-related salary and fringe benefit costs for our research and development projects:
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
In April 2023, in connection with the Burlington Lease, we entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023 we began funding into an escrow account maintained by the escrow agent a portion of our share of tenant improvement construction costs at the facility, which is designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. The Company funded the remaining 50% of its required cost amount, or approximately $28.3 million, with cash on hand, pursuant to the Construction Escrow Agreement in April 2024. Additionally, and in order to support the expansion of our autologous cell manufacturing operations at the new facility in Burlington, we have and continue to invest in the acquisition and installation of certain specialized manufacturing and laboratory equipment.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedMD&A
The overall decreases decrease in cash from our working capital accounts were was primarily driven by an increase in accounts receivable due to higher sales volume and payments on operating leases, partially offset by an increase in sales volume, offset by a decrease in inventory due to usage for production needs, an increase of accounts payable and accrued expenses due to timing of payments and receipts of tenant improvement allowances which exceeded payments on operating leases amortization. payments.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The $35.3 $51.9 million of net cash provided by operations in 2023, 2025, was primarily the result of net income of $16.5 million, non-cash charges of $32.3 $38.8 million related to stock compensation expense, $6.1 million in operating lease amortization and $4.6 $11.5 million in depreciation and amortization expense, expense and $5.4 million in operating lease amortization, partially offset by a net loss of $3.2 million and a net decrease of $4.1 $22.4 million related to movements in our working capital accounts.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The overall decrease in cash from our working capital accounts was primarily driven by an increase in inventory primarily related to supporting NexoBrid commercial availability and an increase in accounts receivable due to higher sales volume, partially offset by an increase in operating lease liabilities due to receipts of tenant improvement allowances which exceeded payments on operating leases amortization.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Our portfolio of commercial-stage products also includes NexoBrid (anacaulase-bcdb), a topically-administered biological orphan product containing proteolytic enzymes, for which the FDA approved a BLA in December 2022 permitting the product’s use for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. 2022.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Total revenue increase for the year ended December 31, 2024, 2025, compared to 2023, 2024, was driven primarily by MACI volume and price growth, in addition to higher Epicel growth and NexoBrid volume growth, partially offset by lower Epicel volume.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2025 2024 2023 2022 Net cash provided by operating activities $ 51,910 $ 58,163 $ 35,311 $ 17,687 Net cash used in investment activities (43,937) (79,034) (3,130) (36,206) Net cash provided by financing activities 7,070 19,054 3,618 1,045 Net increase (decrease) increase in cash, cash equivalents, and restricted cash $ 15,043 $ (1,817) $ 35,799 $ (17,474)
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Our cash, cash and cash equivalents and restricted cash totaled $86.9 $100.1 million, short-term investments totaled $40.5 $37.4 million and long-term investments totaled $25.3 $61.4 million as of December 31, 2023. 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Total remaining obligations related to operating and finance leases are $146.0 million, with $4.4 $132.3 million of tenant improvement allowances allowed for, as of December 31, 2024. 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
In the last five years through 2024, 2025, MACI sales volumes from the first through the fourth quarter on average represented 21% (20%-22% range), 23% (22%-24% range), 22% (16%-24% range), 23% (21%-26% (21%-24% range) and 34% (33%-38% (33%-34% range) respectively, of total annual volumes.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We also are evaluating the feasibility and potential market opportunity involved in focused on delivering MACI treatment to patients suffering from cartilage damage in the ankle.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Epicel is regulated by CBER of the FDA FDA’s Center for Biologics Evaluation and Research (“CBER”) under medical device authorities, and is the only FDA-approved cultured epidermal autograft product available for large total surface area burns in both adult and pediatric patients.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Gross profit increased for the year ended December 31, 2024, 2025, compared to the same period in 2023, 2024, primarily driven by MACI revenue growth across all products, combined with our primarily fixed manufacturing cost structure, which consists mainly of labor and facility costs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesMD&A
The Burlington facility is substantially complete, and we are currently utilizing the facility’s office space.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesMD&A
The arthroscopic delivery of MACI could may increase the ease of MACI’s use for physicians and may reduce both the length of the procedure as well as procedure-induced trauma, which may result in a reduction of a patient’s post-operative pain and accelerate a patient’s recovery.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesMD&A
NexoBrid’s FDA approval expands our burn care franchise’s total addressable market, which will permit permits us to treat a significantly larger segment of hospitalized burn patients than with Epicel alone.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new